Britta Hahn1, Mohammed Shoaib, Ian P Stolerman. 1. University of Maryland School of Medicine, Maryland Psychiatric Research Center, P.O. Box 21247, Baltimore, MD 21228, USA. bhahn@mprc.umaryland.edu
Abstract
RATIONALE: The question of the subtype(s) of the nicotinic acetylcholine receptor (nAChR) mediating the attention-enhancing effects of nicotine is still unsettled. While early studies pointed towards subtypes other than the homomeric α7 nAChR, pro-cognitive effects of α7 nAChR agonists have since been demonstrated. OBJECTIVES: This study tested whether the performance-enhancing effects of nicotine in a rodent model of attention could be reversed by the α4β2, α4β4, α3β2, and α2β2 nAChR antagonist dihydro-β-erythroidine (DHβE), or the α7 antagonist methyllycaconitine (MLA). METHODS: In repeated tests, 12 rats trained to perform the 5-choice serial reaction time task were systemically injected with nicotine or vehicle in the presence of increasing doses of DHβE or MLA. RESULTS: DHβE did not antagonize the attention-enhancing effects of nicotine reflected by measures of accuracy and omission errors, suggesting that its previously reported antagonism of nicotine effects on latency and anticipatory responses specifically reflected the stimulant effects of nicotine. MLA dose-dependently reversed the reduction in omission errors by nicotine. In the absence of nicotine, low doses of MLA (0.4 and 1.3 mg/kg) not previously tested on attention improved response accuracy, resulting in an inverted U-shape dose-response function. CONCLUSIONS: nAChR subtypes involved in the performance-enhancing effects of nicotine appear to vary depending on the function assessed. Our findings suggest a greater involvement of α7 nAChRs in the effects of nicotine on attention than first suggested by preclinical studies, with different optimal receptor tones for aspects of stimulus detection and response readiness to task stimuli.
RATIONALE: The question of the subtype(s) of the nicotinic acetylcholine receptor (nAChR) mediating the attention-enhancing effects of nicotine is still unsettled. While early studies pointed towards subtypes other than the homomeric α7 nAChR, pro-cognitive effects of α7 nAChR agonists have since been demonstrated. OBJECTIVES: This study tested whether the performance-enhancing effects of nicotine in a rodent model of attention could be reversed by the α4β2, α4β4, α3β2, and α2β2 nAChR antagonist dihydro-β-erythroidine (DHβE), or the α7 antagonist methyllycaconitine (MLA). METHODS: In repeated tests, 12 rats trained to perform the 5-choice serial reaction time task were systemically injected with nicotine or vehicle in the presence of increasing doses of DHβE or MLA. RESULTS: DHβE did not antagonize the attention-enhancing effects of nicotine reflected by measures of accuracy and omission errors, suggesting that its previously reported antagonism of nicotine effects on latency and anticipatory responses specifically reflected the stimulant effects of nicotine. MLA dose-dependently reversed the reduction in omission errors by nicotine. In the absence of nicotine, low doses of MLA (0.4 and 1.3 mg/kg) not previously tested on attention improved response accuracy, resulting in an inverted U-shape dose-response function. CONCLUSIONS:nAChR subtypes involved in the performance-enhancing effects of nicotine appear to vary depending on the function assessed. Our findings suggest a greater involvement of α7 nAChRs in the effects of nicotine on attention than first suggested by preclinical studies, with different optimal receptor tones for aspects of stimulus detection and response readiness to task stimuli.
Authors: A R Davies; D J Hardick; I S Blagbrough; B V Potter; A J Wolstenholme; S Wonnacott Journal: Neuropharmacology Date: 1999-05 Impact factor: 5.250
Authors: A J Grottick; G Trube; W A Corrigall; J Huwyler; P Malherbe; R Wyler; G A Higgins Journal: J Pharmacol Exp Ther Date: 2000-09 Impact factor: 4.030
Authors: Simon Sydserff; E J Sutton; Dekun Song; Michael C Quirk; Carla Maciag; Chaoying Li; Gerald Jonak; David Gurley; John C Gordon; Edward P Christian; James J Doherty; Tom Hudzik; Edwin Johnson; Ladislav Mrzljak; Tim Piser; Gennady N Smagin; Yi Wang; Dan Widzowski; Jeffrey S Smith Journal: Biochem Pharmacol Date: 2009-07-16 Impact factor: 5.858
Authors: F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-06-06 Impact factor: 8.989
Authors: K K Higa; A Grim; M E Kamenski; J van Enkhuizen; X Zhou; K Li; J C Naviaux; L Wang; R K Naviaux; M A Geyer; A Markou; J W Young Journal: Psychopharmacology (Berl) Date: 2017-02-28 Impact factor: 4.530
Authors: Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin Journal: Pharmacol Biochem Behav Date: 2013-04-18 Impact factor: 3.533